Pleco Therapeutics Announces the Appointment of Dr. Henno Welgemoed as Chief Medical Officer
Retrieved on:
Tuesday, September 5, 2023
Pancreatic cancer, Heart, Medical Affairs Bureau, University, Bachelor of Medicine, Bachelor of Surgery, Pleco, Infection, Cancer, CMO, Trial of the century, University of Pretoria Faculty of Veterinary Science, Carcinoma, SCLC, AML, Chelation, Henno, Patient, Health, Therapy, Pharmaceutical industry
NIJMEGEN, Netherlands, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Pleco Therapeutics BV, a specialty pharmaceutical company developing novel Plecoid™ therapies designed to detoxify the cancer microenvironment, today announces the appointment of Dr. Henno Welgemoed in the newly created role of Chief Medical Officer (CMO).
Key Points:
- NIJMEGEN, Netherlands, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Pleco Therapeutics BV, a specialty pharmaceutical company developing novel Plecoid™ therapies designed to detoxify the cancer microenvironment, today announces the appointment of Dr. Henno Welgemoed in the newly created role of Chief Medical Officer (CMO).
- Dr. Welgemoed is a qualified physician with 15 years of clinical expertise and over two decades of pharmaceutical experience.
- Ivo Timmermans, Chief Executive Officer of Pleco Therapeutics, said: "I am thrilled to welcome Dr. Henno Welgemoed to the Pleco Therapeutics family as our Chief Medical Officer.
- ‘‘I am very excited to join the Pleco Therapeutics team as CMO to support and accelerate the bench to bedside development of Plecoid™ therapies to improve outcomes for patients,’’ added Dr. Henno Welgemoed, newly appointed Chief Medical Officer of Pleco Therapeutics.